LRRC59 has been shown to be a binding transporter of the cellular inhibitor PP2A (CIP2A) in prostate cancer,6 and its fusion transcripts are present in various malignancies such as ovarian, esophageal, and prostate cancers.7, 8. Here, PTPA is linked to prostate carcinoma.